• PUT A STOP TO THE INSANITY OF ALZHEIMER’S DISEASE TREATMENT

    Posted September 30, 2017: by Bill Sardi

    CALL TO ACTION
    Dietary Supplement Aficionados:
    You Have A Once In A Lifetime Opportunity To Help Recruit Patients For A Study That Could Once & For All Prove A Simple Vitamin Pill Can Prevent & Reverse The Most Dreaded Of All Illnesses – Alzheimer’s Disease.

    The study is being conducted at the Burke Rehabilitation & Research Hospital in White Plains, New York under the direction of Dr. Gary E. Gibson PhD.

    In a pilot study other researchers overseas just reported a small number of patients (5) taking a fat-soluble form of vitamin B1 experienced restoration of some of their mental faculties and regeneration of brain activity as evidenced by PET scans.   The PET scan images are remarkable.   The scrambled brains of Alzheimer’s subjects regained youthful activity once again!

    Hear Bill Sardi live this Saturday Sept. 30, 2017 on the HEALTHY BY NATURE SHOW (Dallas, Tx, syndicated nationally) with nutritionist Martie Whittekin talk about this exciting breakthrough in brain health, or listen to a taped show.

    The U.S. study is stalled as 68 subjects have enrolled but investigators need 74 enrollees to produce statistically valid results.  Individuals with mild Alzheimer’s disease or cognitive impairment over 60 years of age may be eligible to enroll.

    Whether you live in the White Plains area of New York or have loved ones or friends who do, get on the phone, email, blog spots, whatever means of communication, and roust up an army to help Gary E. Gibson PhD and colleagues recruit patients for this all-important study.

    Doctors who diagnose Alzheimer’s disease in the New York area are in special contact with many patients who meet the study enrollment criteria.  Urge them to recruit patients.  Get on blogs, newspaper editorial pages, call your friends in New York and urge them to help too.  Don’t let this moment in history pass by.

    The recruitment desk for the study can be reached by calling Rosanna Cirio at the Burke Rehab Hospital at 914 597-24767 or email at rcirio@burke.org.  The recruitment flyer can be accessed online at www.burke.com

    Growing evidence

    The evidence is growing.  A case report of a woman with mental decline who rapidly responded to vitamin B1 (Benfotiamine) therapy is compelling.

    This author began writing reports in 2012 and 2013 about vitamin B1 as a remedy for this fearful form of memory loss.  A cure for Alzheimer’s disease is at hand.

    Dr. Gibson says many of his investigators report remarkable anecdotal stories about subjects already enrolled in the study.  But Dr. Gibson cannot break open the code to the study and determine which subjects were getting vitamin B1 (Benfotiamine) and which ones are taking an inactive placebo pill until full enrollment is achieved.

    Modern medicine has lost its mind

    All currently used drugs for Alzheimer’s memory loss (Aricept-donepezil, Razadyne-galantamine, Namenda-memantine) are ineffective.  Tacrine, a once widely used drug for Alzheimer’s, is no longer considered useful.

    There are 105 drug studies underway involving Alzheimer’s disease that either help eradicate undesirable brain plaques (beta amyloid or tau protein, which are not evident in all patients with Alzheimer’s) or attempt to allay symptoms of the disease.

    The terrible cost of care

    Alzheimer’s disease now affects 5.5 million Americans.  It now costs $259 billion to treat Alzheimer’s disease and other forms of dementia.  It costs $287,000 to care for an Alzheimer’s patient in the last five years of their life ($157/day).  It would cost only 23-cents a day to provide a 300 milligram vitamin B1 (Benfotiamine) pill (or just $1,265,000 for all 5.5 adults affected by Alzheimer’s memory loss.

    The cost to provide ~170 million American adults over age 35 with a vitamin B1 (Benfotiamine) pill (@ 23-cents for a 300 milligram pill) would be $39 million a year, saving billions of dollars.

    Symptoms of Alzheimer’s

    Symptoms of Alzheimer’s include difficulty thinking; mental confusion especially in the evening hours; inability to create new memories, difficulty doing simple math (checkbook); agitation; repetition of words; anger; hallucination; loss of appetite; jumbled speech; loss of smell.

    And to think that the highly absorbable form of vitamin B1 (Benfotamine) has been available since the early 1950s.  A cure may have been at hand for the past six-plus decades but ignored by the drug-oriented medical establishment.

    Don’t let history repeat itself

    Don’t let Big Pharma throw vitamin therapy under the rug again as it did when Dr. Linus Pauling demonstrated in the 1970s that vitamin C therapy produced longer survival times than chemotherapy at that time.  Only now, 5+ decades later, is vitamin C therapy for cancer being reassessed because of promising new studies.

    Failure to detect odors predicts Alzheimer’s

    It is no coincidence that a recently published study indicates failure to detect odors is an early sign of mental decline.   Vitamin B1 (thiamin) deficiency results in massive cell death of olfactory nerves located at the top of the nasal cavity.

    All subjects age 57-85 years of age who were unable to detect five scents (peppermint, fish, orange, rose and leather) developed dementia within 5 years.   Eighty-percent who detected only one or two scents also developed dementia within 5 years.  Loss of scent is a better predictor of death than a diagnosis of heart failure or cancer.

    Brain plaque also linked to vitamin deficiency

    Nor is it a surprise to learn that vitamin B1 deficiency leads to accumulation of beta amyloid brain plaque that is associated with Alzheimer’s disease.

    Thiamin is also a precursor for acetylcholine, a transmitter of nerve impulses.  A number of drugs (Tacrine/Cognex, Razadyne/galantamine, Aricept/donepezil) attempt to improve memory by inhibition of acetylcholinesterase, the enzyme that degrades this brain chemical.  However, this class of drugs is not cost effective.

    This means modern pharmacology has been hiding the fact that a vitamin deficiency is at the root of mental decline in humans.  All efforts to develop synthetic drugs are inappropriate.

    What Big Pharma has planned

    Big Pharma is already counting its profits.  Wall Street is already planning on three drugs that alleviate symptoms of Alzheimer’s earning $7 billion in sales by 2023.  Big Pharma forecasts $12 billion in sales of inappropriate drugs for Alzheimer’s disease, triple what is now spent for drug therapy.  Powerful forces will be working against vitamin therapy, including the news media that serves Big Pharma.

    Start vitamin therapy now.  Let the science catch up later

    Let’s put a stop to all the insanity surrounding Alzheimer’s drug therapy.   If you have a loved one in the grip of Alzheimer’s disease or have a family history of this mind-deteriorating disorder, this author suggests vitamin B1 therapy (300 mg Benfotiamine) begin now.  There is little to lose.

    There is evidence that lower doses of vitamin B1 may be effective as no more than 8.3 milligrams of vitamin B1 hydrochloride (the common form of B1 in multivitamins) is absorbed.  Malabsorption of B1 is a major problem as alcohol, sugar, refined carbohydrates, coffee, tea, drugs and lack of stomach acid impair absorption.  Benfotiamine is far-better absorbed and is effective but does not cross the blood-brain barrier.   Allithiamine (thiamin disulfide) is more potent form of B1 that traverses the blood brain barrier but is untested for brain disorders such as Alzheimer’s.  In humans, oral allithiamine is equivalent to intravenous administration of B1.

    According to a landmark study of the effectiveness of different forms of vitamin B1, in humans, the common form of water soluble B1 (thiamin hydrochloride) increases blood levels by 50% compared to a 347% increase with allithiamine.   Allithiamine raises blood levels among B1-sufficient individuals 5.3 times better than thiamin hydrochloride and ~13 times better among B1-deficient subjects.   (For interpretation, 20 mg of allithiamine is roughly equivalent to 100-260 mg of thiamine hydrochloride).

    Only one multivitamin (MOLECULAR MULTI), formulated by this author, provides Benfotiamine (5 mg) and/or allithiamine (tetrahydrofufuryl disulfide 20 mg) + vitamin B12 necessary to avert brain shrinkage along with folic acid reduce homocysteine levels.

    Within days of hearing about this breakthrough individuals email me to say they observe behavioral improvements in their loved ones already.  – Bill Sardi, Knowledge of Health at www.knowledgeofhealth.com Sept. 29, 2017.

    Posted in Brain ; No Comments »

Comments are closed.